research use only

L-NMMA acetate NOS inhibitor

Name: L-NMMA acetate
Brand: Selleck Chemicals
SKU: S7920
Availability: InStock
Rating: 5 (3 reviews)

Cat.No.S7920

L-NMMA acetate (Tilarginine Acetate, Methylarginine acetate, NG-Monomethyl-L-arginine acetate, L-NG-monomethyl Arginine acetate) is an acetate salt form of L-NMMA. L-NMMA is a nitric oxide synthase(NOS) inhibitor with an IC50 of 4.1 μM for nNOS.

Chemical Structure

Molecular Weight: 248.28

Jump to

Quality Control

Batch: S792001 Water]50 mg/mL]false]DMSO]Insoluble]false]Ethanol]Insoluble]false Purity: 99.82%

Cited in Nature Medicine for its top-tier quality
COA
NMR
HPLC
SDS/MSDS
Datasheet

99.82

Related Targets	PD-1/PD-L1 CXCR STING AhR Immunology & Inflammation related CD markers Interleukins Anti-infection Antioxidant COX
Other NOS Inhibitors	L-NAME HCl 1400W 2HCl TPEN (3R,8S)-Falcarindiol 6-Biopterin 2',5'-Dihydroxyacetophenone ZLc002 Prim-o-glucosylcimifugin L-Canavanine sulfate Bendazol

Solubility

In vitro
Batch:

Water : 50 mg/mL

DMSO : Insoluble
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	248.28	Formula	C₉H₂₀N₄O₄	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	53308-83-1	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	Tilarginine Acetate, Methylarginine acetate, NG-Monomethyl-L-arginine acetate, L-NG-monomethyl Arginine acetate,			SMILES	CNC(=N)NCCCC(N)C(O)=O.CC(O)=O

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	nNOS (Cell-free assay) 4.1 μM
In vitro	As a nitric oxide synthase inhibitor, L-NMMA acetate has the Ki values for nNOS (rat) and iNOS (rat) are approximately 0.18 and 6 µM, respectively.
In vivo	Following L-NMMA acetate administration, skeletal muscle contractile function is dose-dependently decreased with the administration of drug during ischemia/reperfusion (I/R) in vivo.
References	[1] https://pubmed.ncbi.nlm.nih.gov/10025531/ [2] https://pubmed.ncbi.nlm.nih.gov/18391107/ [3] https://pubmed.ncbi.nlm.nih.gov/7523401/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-06-04)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05660083	RECRUITING	HER2-negative Breast Cancer; Metastatic Breast Cancer; Metaplastic Breast Carcinoma; TNBC - Triple-Negative Breast Cancer	The Methodist Hospital Research Institute	2023-01-12	PHASE2
NCT02966665	RECRUITING	Chronic Obstructive Pulmonary Disease; Pulmonary Artery Hypertension; Heart Failure; Hypertension	Russell Richardson	2008-09	PHASE1
NCT01791816	COMPLETED	Vasovagal Syncope; Postural Tachycardia Syndrome	New York Medical College	2013-02	EARLY_PHASE1
NCT03066115	WITHDRAWN	Hypoxia; Hypercapnia	University of Wisconsin, Madison	2020-12-01	PHASE1
NCT03236935	COMPLETED	Non-Small Cell Lung Cancer; Malignant Melanoma; Head and Neck Squamous Cell Carcinoma; Classical Hodgkin Lymphoma; Urothelial Carcinoma Bladder; DNA Repair-Deficiency Disorders	The Methodist Hospital Research Institute	2018-08-27	PHASE1
NCT02834403	COMPLETED	Metastatic Triple Negative Breast Cancer	The Methodist Hospital Research Institute	2016-11	PHASE1; PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):